| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Immunology, IMM-19, The Scripps Research Institute, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA
Epstein—Barr virus (EBV) initiates infection of normal B lymphocytes by binding to CD21, a complement receptor. Since EBV, unlike most viruses, preferentially infects resting (non-activated) cells, the present studies were undertaken to evaluate the hypothesis that intracellular signalling pathway(s) triggered by EBV binding to CD21 activate the expression of certain cellular genes, as well as the initially expressed viral genes, and thus enable EBV to infect resting B cells. Experiments with non-transforming EBV, recombinant virus ligand and anti-CD21 MAbs show that EBV binding to CD21 on resting B cells increases CD23 mRNA levels independently of viral gene expression. A panel of five protein kinase C (PKC) and tyrosine kinase (PTK) inhibitors, all with different modes of action, exhibited a distinctive pattern of effects on the EBV induced induction of CD23 expression, ranging from nearly complete inhibition to no influence. The results suggest that distinct PKC isoforms and PTKs are involved in the signalling pathway(s) triggered by EBV binding to CD21. Significantly, the five inhibitors showed the same pattern of effects on the earliest stages of infection (EBNA-2 transcription) and B cell transformation (mitogenesis and colony formation). The identical pattern of effects of these PKC and PTK inhibitors with diverse mechanisms of action on the EBV induced increase in both CD23 and EBNA-2 mRNA levels strongly suggests that their transcription is mediated by an intracellular signalling pathway which shares, at least in part, common members.
Present address: Isis Pharmaceutical, Carlsbad, Calif., USA.
Present address: R. W. Johnson Pharmaceutical Research Institute, La Jolla, Calif., USA.
Received 25 March 1996;
accepted 6 August 1996.
This article has been cited by other articles:
|
|
 |
|
  J J-Y Lu, D-Y Chen, C-W Hsieh, J-L Lan, F-J Lin, and S-H Lin Association of Epstein-Barr virus infection with systemic lupus erythematosus in Taiwan Lupus, March 1, 2007; 16(3): 168 - 175. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Shannon-Lowe, G. Baldwin, R. Feederle, A. Bell, A. Rickinson, and H.-J. Delecluse Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth J. Gen. Virol., November 1, 2005; 86(11): 3009 - 3019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Poller, H. Fechner, M. Noutsias, C. Tschoepe, M. Pauschinger, and H.-P. Schultheiss The molecular basis of cardiotropic viral infections Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I18 - I30. [Abstract] [PDF]
|
|
|
|
 |
|
 K. L. Mossman, P. F. Macgregor, J. J. Rozmus, A. B. Goryachev, A. M. Edwards, and J. R. Smiley Herpes Simplex Virus Triggers and Then Disarms a Host Antiviral Response J. Virol., January 15, 2001; 75(2): 750 - 758. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Chang, C.-H. Tung, Y.-T. Huang, J. Lu, J.-Y. Chen, and C.-H. Tsai Requirement for Cell-to-Cell Contact in Epstein-Barr Virus Infection of Nasopharyngeal Carcinoma Cells and Keratinocytes J. Virol., October 1, 1999; 73(10): 8857 - 8866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Boyle, R. L. Pietropaolo, and T. Compton Engagement of the Cellular Receptor for Glycoprotein B of Human Cytomegalovirus Activates the Interferon-Responsive Pathway Mol. Cell. Biol., May 1, 1999; 19(5): 3607 - 3613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bruns, S. Miska, S. Chassot, and H. Will Enhancement of Hepatitis B Virus Infection by Noninfectious Subviral Particles J. Virol., February 1, 1998; 72(2): 1462 - 1468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Makar, C. T. N. Pham, M. H. Dehoff, S. M. O'Connor, S. M. Jacobi, and V. M. Holers An Intronic Silencer Regulates B Lymphocyte Cell- and Stage-Specific Expression of the Human Complement Receptor Type 2 (CR2, CD21) Gene J. Immunol., February 1, 1998; 160(3): 1268 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sugano, W. Chen, M. L. Roberts, and N. R. Cooper Epstein-Barr Virus Binding to CD21 Activates the Initial Viral Promoter via NF-kappa B Induction J. Exp. Med., August 29, 1997; 186(5): 731 - 737. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
